Bausch + Lomb Stock
Bausch + Lomb Corporation
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- Canada
- CEO
- Thomas J. Appio
- Employees
- 13,000
- Market cap
- $8.3 B
- IPO
- 06/05/2022
Bausch + Lomb Corporation is a global leader in the healthcare sector, specializing in eye health through a wide range of products and services. Founded in 1853, the company is headquartered in Vaughan, Canada. The business operations are organized into three key areas: Vision Care/Consumer Health Care, Ophthalmic…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Bausch + Lomb stock: price history
1D
-1.6%
1W
-6.5%
1M
-3.2%
6M
+0.0%
YTD
-1.4%
1Y
+11.0%
2Y
-18.9%
5Y
–
10Y
–
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~44% stronger price swings than usual
Ask the agents about Bausch + Lomb
Analyst assessment of Bausch + Lomb
0
STRONG BUY
6
BUY
8
HOLD
1
SELL
0
STRONG SELL
15
TOTAL · Hold
As of: 15/09/2026
Bausch + Lomb stock metrics
P/E
-34.48
P/B
0.92
EV/EBITDA
14.34
RETURN ON EQUITY
-0.2%
NET MARGIN
-1.0%
DEBT/EQUITY
0.8
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
12.9%
FLOAT SHARES
46,060,030
AVG. DAILY VOLUME (30D)
1,578
Comparable stocks
Frequently asked questions about Bausch + Lomb stock
What does Bausch + Lomb do?
Bausch + Lomb Corporation is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in Canada.
The CEO is Thomas J. Appio, the company employs around 13,000 people.
The IPO was on 06/05/2022; the stock trades on TSX under the ticker BLCO.TO.
What do analysts say about Bausch + Lomb stock?
15 analysts rate the stock, the consensus is Hold (as of 15/09/2026).
This is an external assessment, not a statement by Market Jury.
When does Bausch + Lomb report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly 44% stronger than usual.
Does Bausch + Lomb pay a dividend?
No, Bausch + Lomb currently does not pay a dividend.
Which stocks are comparable to Bausch + Lomb?
Comparable stocks include Bausch + Lomb, Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Sartorius, Solventum and Baxter International.
How can I get Bausch + Lomb stock analyzed?
Clicking "Analyze stock" lets five strategies assess Bausch + Lomb against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.